Targeting the Virus: A Guide to COVID-19 Antiviral Therapies
PA Yoke shares information about the antiviral medications available for the treatment of COVID-19. She highlights the mechanisms of action, dosing, efficacy, and safety information related to 3 antiviral options, providing practical tips for identifying appropriate patients for each medication. By the end of the video, PAs have a clear framework for evaluating medications for treatment of COVID-19 in high-risk patients early in the course of disease.
Key Takeaways:
- Antiviral medications should be initiated within 5 days of symptom development in high-risk patients.
- There are two oral antiviral options for outpatient treatment, each with their own considerations.
Speaker
Click on the photo below to learn more about the speaker.
References and Additional Resources:
Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020;371:m3862. doi:10.1136/bmj.m3862
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Accessed August 12, 2025. htps://www.ncbi.nlm.nih.gov/books/NBK570371/pdf/Bookshelf_NBK570371.pdf
Gulick RM, Pau AK, Daar E, et al. National Institutes of health COVID-19 Treatment Guidelines Panel: Perspectives and lessons learned. Ann Intern Med. 2024;177(11):1547-1557. doi:10.7326/ANNALS-24-00464
IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Idsociety.org. Accessed August 12, 2025. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/
Supported by
